Skip to main content

Aisling Capital Management LP

13F filer · CIK 0001766721
Reported Aug 13, 2026
Net seller this quarter
13F portfolio value$472MU.S. long equity reported on 13F
Positions141 new · 0 closed
Net flow last quarter-$35.4MBuys minus sells
Top 10 positions weight99.0%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 13, 202614 positions
BBIOBridgeBio Pharma, Inc.$342M72.48%2.35%-9.8%Q2 2019
GLUEMonte Rosa Therapeutics, Inc.$37.6M7.98%1.83%Not reportedQ2 2021
SNDXSyndax Pharmaceuticals Inc$28.8M6.10%1.48%Not reportedQ1 2020
CMPSCOMPASS Pathways plc$20.3M4.30%1.06%Not reportedQ3 2023
BCAXBicara Therapeutics Inc.$16.9M3.58%0.86%Not reportedQ3 2024
BBOTBridgeBio Oncology Therapeutics, Inc.$7.76M1.64%1.27%Not reportedQ3 2025
SRRKScholar Rock Holding Corp$4.24M0.90%0.06%Not reportedQ3 2025
URGNUroGen Pharma Ltd.$3.97M0.84%0.22%Not reportedQ4 2025
BMEABiomea Fusion, Inc.$3.01M0.64%2.83%Not reportedQ2 2021
ACRSAclaris Therapeutics, Inc.$2.3M0.49%0.31%Not reportedQ4 2018
EPRXEupraxia Pharmaceuticals Inc.$2.15M0.46%0.63%Not reportedQ1 2026
VTVTvTv Therapeutics Inc.$1.88M0.40%Not reportedNewQ2 2026
MRKRMarker Therapeutics, Inc.$478K0.10%1.95%Not reportedQ4 2018
OKUROnKure Therapeutics, Inc.$404K0.09%0.22%Not reportedQ4 2024
Q1 2026Reported May 5, 202613 positions
BBIOBridgeBio Pharma, Inc.$378M79.35%2.60%Not reportedQ2 2019
SNDXSyndax Pharmaceuticals Inc$30.8M6.46%1.49%Not reportedQ1 2020
GLUEMonte Rosa Therapeutics, Inc.$25.6M5.37%1.84%+5.7%Q2 2021
BCAXBicara Therapeutics Inc.$11.3M2.38%0.87%Not reportedQ3 2024
BBOTBridgeBio Oncology Therapeutics, Inc.$9.11M1.91%1.27%+80.3%Q3 2025
CMPSCOMPASS Pathways plc$7.92M1.66%1.06%+19.5%Q3 2023
SRRKScholar Rock Holding Corp$3.79M0.80%0.06%Not reportedQ3 2025
BMEABiomea Fusion, Inc.$3.13M0.66%2.83%Not reportedQ2 2021
EPRXEupraxia Pharmaceuticals Inc.$2.35M0.49%0.63%NewQ1 2026
URGNUroGen Pharma Ltd.$1.94M0.41%0.22%Not reportedQ4 2025
ACRSAclaris Therapeutics, Inc.$1.63M0.34%0.31%Not reportedQ4 2018
MRKRMarker Therapeutics, Inc.$423K0.09%1.95%Not reportedQ4 2018
OKUROnKure Therapeutics, Inc.$367K0.08%0.65%Not reportedQ4 2024
Q4 2025Reported Feb 10, 202613 positions
BBIOBridgeBio Pharma, Inc.$389M81.29%2.61%-16.4%Q2 2019
SNDXSyndax Pharmaceuticals Inc$27.7M5.78%1.51%Not reportedQ1 2020
GLUEMonte Rosa Therapeutics, Inc.$23.1M4.82%2.25%Not reportedQ2 2021
BCAXBicara Therapeutics Inc.$9.57M2.00%1.01%Not reportedQ3 2024
CMPSCOMPASS Pathways plc$8.27M1.73%1.25%Not reportedQ3 2023
BBOTBridgeBio Oncology Therapeutics, Inc.$7.07M1.48%0.71%Not reportedQ3 2025
CALCCalciMedica, Inc.$3.43M0.72%3.38%Not reportedQ1 2024
SRRKScholar Rock Holding Corp$3.39M0.71%0.07%Not reportedQ3 2025
BMEABiomea Fusion, Inc.$2.54M0.53%2.83%Not reportedQ2 2021
URGNUroGen Pharma Ltd.$2.53M0.53%0.22%NewQ4 2025
ACRSAclaris Therapeutics, Inc.$1.31M0.27%0.36%Not reportedQ4 2018
MRKRMarker Therapeutics, Inc.$485K0.10%1.95%Not reportedQ4 2018
OKUROnKure Therapeutics, Inc.$257K0.05%26.50%Not reportedQ4 2024
Q3 2025Reported Nov 12, 202514 positions
BBIOBridgeBio Pharma, Inc.$316M69.29%3.16%+0.4%Q2 2019
VRNAVerona Pharma plc$65.7M14.39%0.09%Not reportedQ4 2018
SNDXSyndax Pharmaceuticals Inc$20.3M4.44%1.52%Not reportedQ1 2020
NUVBNuvation Bio Inc.$11M2.40%0.88%+16.5%Q1 2021
GLUEMonte Rosa Therapeutics, Inc.$10.9M2.39%2.38%Not reportedQ2 2021
BCAXBicara Therapeutics Inc.$8.98M1.97%1.04%Not reportedQ3 2024
CMPSCOMPASS Pathways plc$6.87M1.50%1.25%Not reportedQ3 2023
BBOTBridgeBio Oncology Therapeutics, Inc.$6.54M1.43%0.71%NewQ3 2025
BMEABiomea Fusion, Inc.$4.14M0.91%3.44%Not reportedQ2 2021
SRRKScholar Rock Holding Corp$2.87M0.63%0.08%NewQ3 2025
CALCCalciMedica, Inc.$1.6M0.35%3.66%Not reportedQ1 2024
ACRSAclaris Therapeutics, Inc.$825K0.18%0.40%Not reportedQ4 2018
MRKRMarker Therapeutics, Inc.$290K0.06%1.95%Not reportedQ4 2018
OKUROnKure Therapeutics, Inc.$244K0.05%26.50%Not reportedQ4 2024
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.